Selected research
Industry Research
Pegylated Liposomal Doxorubicin Industry Research Report 2026
Market perspective
The global Pegylated Liposomal Doxorubicin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pegylated Liposomal Doxorubicin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pegylated Liposomal Doxorubicin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pegylated Liposomal Doxorubicin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pegylated Liposomal Doxorubicin include Fudan Zhangjiang, Changzhou Jinyuan, Sun Pharma, Plus Therapeutics, J&J Janssen, Ipsen, Dr. Reddy's Laboratories and CSPC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pegylated Liposomal Doxorubicin market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pegylated Liposomal Doxorubicin Market by Company
Fudan Zhangjiang
Changzhou Jinyuan
Sun Pharma
Plus Therapeutics
J&J Janssen
Ipsen
Dr. Reddy's Laboratories
CSPC
Pegylated Liposomal Doxorubicin Segment by Type
Branded Pegylated Liposomal Doxorubicin
Generic Pegylated Liposomal Doxorubicin
Pegylated Liposomal Doxorubicin Segment by Application
Hospital
Research Organizations
Others
Pegylated Liposomal Doxorubicin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pegylated Liposomal Doxorubicin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pegylated Liposomal Doxorubicin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pegylated Liposomal Doxorubicin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pegylated Liposomal Doxorubicin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pegylated Liposomal Doxorubicin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pegylated Liposomal Doxorubicin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Branded Pegylated Liposomal Doxorubicin
- Generic Pegylated Liposomal Doxorubicin
Applications
- Hospital
- Research Organizations
- Others
Companies covered
- Fudan Zhangjiang
- Changzhou Jinyuan
- Sun Pharma
- Plus Therapeutics
- J&J Janssen
- Ipsen
- Dr. Reddy's Laboratories
- CSPC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pegylated Liposomal Doxorubicin Market Size (2021-2032)
- 2.2.2 Global Pegylated Liposomal Doxorubicin Sales (2021-2032)
- 2.2.3 Global Pegylated Liposomal Doxorubicin Market Average Price (2021-2032)
- 2.3 Pegylated Liposomal Doxorubicin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Branded Pegylated Liposomal Doxorubicin
- 2.3.3 Generic Pegylated Liposomal Doxorubicin
- 2.4 Pegylated Liposomal Doxorubicin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Research Organizations
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pegylated Liposomal Doxorubicin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pegylated Liposomal Doxorubicin Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Pegylated Liposomal Doxorubicin Revenue of Manufacturers (2021-2026)
- 3.4 Global Pegylated Liposomal Doxorubicin Average Price by Manufacturers (2021-2026)
- 3.5 Global Pegylated Liposomal Doxorubicin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pegylated Liposomal Doxorubicin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pegylated Liposomal Doxorubicin, Product Type & Application
- 3.8 Global Manufacturers of Pegylated Liposomal Doxorubicin, Established Date
- 3.9 Global Pegylated Liposomal Doxorubicin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Fudan Zhangjiang
- 4.1.1 Fudan Zhangjiang Company Information
- 4.1.2 Fudan Zhangjiang Business Overview
- 4.1.3 Fudan Zhangjiang Pegylated Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Fudan Zhangjiang Pegylated Liposomal Doxorubicin Product Portfolio
- 4.1.5 Fudan Zhangjiang Recent Developments
- 4.2 Changzhou Jinyuan
- 4.2.1 Changzhou Jinyuan Company Information
- 4.2.2 Changzhou Jinyuan Business Overview
- 4.2.3 Changzhou Jinyuan Pegylated Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Changzhou Jinyuan Pegylated Liposomal Doxorubicin Product Portfolio
- 4.2.5 Changzhou Jinyuan Recent Developments
- 4.3 Sun Pharma
- 4.3.1 Sun Pharma Company Information
- 4.3.2 Sun Pharma Business Overview
- 4.3.3 Sun Pharma Pegylated Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sun Pharma Pegylated Liposomal Doxorubicin Product Portfolio
- 4.3.5 Sun Pharma Recent Developments
- 4.4 Plus Therapeutics
- 4.4.1 Plus Therapeutics Company Information
- 4.4.2 Plus Therapeutics Business Overview
- 4.4.3 Plus Therapeutics Pegylated Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Plus Therapeutics Pegylated Liposomal Doxorubicin Product Portfolio
- 4.4.5 Plus Therapeutics Recent Developments
- 4.5 J&J Janssen
- 4.5.1 J&J Janssen Company Information
- 4.5.2 J&J Janssen Business Overview
- 4.5.3 J&J Janssen Pegylated Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 J&J Janssen Pegylated Liposomal Doxorubicin Product Portfolio
- 4.5.5 J&J Janssen Recent Developments
- 4.6 Ipsen
- 4.6.1 Ipsen Company Information
- 4.6.2 Ipsen Business Overview
- 4.6.3 Ipsen Pegylated Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ipsen Pegylated Liposomal Doxorubicin Product Portfolio
- 4.6.5 Ipsen Recent Developments
- 4.7 Dr. Reddy's Laboratories
- 4.7.1 Dr. Reddy's Laboratories Company Information
- 4.7.2 Dr. Reddy's Laboratories Business Overview
- 4.7.3 Dr. Reddy's Laboratories Pegylated Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Dr. Reddy's Laboratories Pegylated Liposomal Doxorubicin Product Portfolio
- 4.7.5 Dr. Reddy's Laboratories Recent Developments
- 4.8 CSPC
- 4.8.1 CSPC Company Information
- 4.8.2 CSPC Business Overview
- 4.8.3 CSPC Pegylated Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CSPC Pegylated Liposomal Doxorubicin Product Portfolio
- 4.8.5 CSPC Recent Developments
5 Global Pegylated Liposomal Doxorubicin Market Scenario by Region
- 5.1 Global Pegylated Liposomal Doxorubicin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pegylated Liposomal Doxorubicin Sales by Region: 2021-2032
- 5.2.1 Global Pegylated Liposomal Doxorubicin Sales by Region: 2021-2026
- 5.2.2 Global Pegylated Liposomal Doxorubicin Sales by Region: 2027-2032
- 5.3 Global Pegylated Liposomal Doxorubicin Revenue by Region: 2021-2032
- 5.3.1 Global Pegylated Liposomal Doxorubicin Revenue by Region: 2021-2026
- 5.3.2 Global Pegylated Liposomal Doxorubicin Revenue by Region: 2027-2032
- 5.4 North America Pegylated Liposomal Doxorubicin Market Facts & Figures by Country
- 5.4.1 North America Pegylated Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pegylated Liposomal Doxorubicin Sales by Country (2021-2032)
- 5.4.3 North America Pegylated Liposomal Doxorubicin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Pegylated Liposomal Doxorubicin Market Facts & Figures by Country
- 5.5.1 Europe Pegylated Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pegylated Liposomal Doxorubicin Sales by Country (2021-2032)
- 5.5.3 Europe Pegylated Liposomal Doxorubicin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Pegylated Liposomal Doxorubicin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pegylated Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pegylated Liposomal Doxorubicin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pegylated Liposomal Doxorubicin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pegylated Liposomal Doxorubicin Market Facts & Figures by Country
- 5.7.1 South America Pegylated Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pegylated Liposomal Doxorubicin Sales by Country (2021-2032)
- 5.7.3 South America Pegylated Liposomal Doxorubicin Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Pegylated Liposomal Doxorubicin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pegylated Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pegylated Liposomal Doxorubicin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pegylated Liposomal Doxorubicin Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Pegylated Liposomal Doxorubicin Sales by Type (2021-2032)
- 6.1.1 Global Pegylated Liposomal Doxorubicin Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Pegylated Liposomal Doxorubicin Sales Market Share by Type (2021-2032)
- 6.2 Global Pegylated Liposomal Doxorubicin Revenue by Type (2021-2032)
- 6.2.1 Global Pegylated Liposomal Doxorubicin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pegylated Liposomal Doxorubicin Revenue Market Share by Type (2021-2032)
- 6.3 Global Pegylated Liposomal Doxorubicin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pegylated Liposomal Doxorubicin Sales by Application (2021-2032)
- 7.1.1 Global Pegylated Liposomal Doxorubicin Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Pegylated Liposomal Doxorubicin Sales Market Share by Application (2021-2032)
- 7.2 Global Pegylated Liposomal Doxorubicin Revenue by Application (2021-2032)
- 7.2.1 Global Pegylated Liposomal Doxorubicin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pegylated Liposomal Doxorubicin Revenue Market Share by Application (2021-2032)
- 7.3 Global Pegylated Liposomal Doxorubicin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pegylated Liposomal Doxorubicin Value Chain Analysis
- 8.1.1 Pegylated Liposomal Doxorubicin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pegylated Liposomal Doxorubicin Production Mode & Process
- 8.2 Pegylated Liposomal Doxorubicin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pegylated Liposomal Doxorubicin Distributors
- 8.2.3 Pegylated Liposomal Doxorubicin Customers
9 Global Pegylated Liposomal Doxorubicin Analyzing Market Dynamics
- 9.1 Pegylated Liposomal Doxorubicin Industry Trends
- 9.2 Pegylated Liposomal Doxorubicin Industry Drivers
- 9.3 Pegylated Liposomal Doxorubicin Industry Opportunities and Challenges
- 9.4 Pegylated Liposomal Doxorubicin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst